WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017204316) 5-OXO-1,2,4-TRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/204316    International Application No.:    PCT/JP2017/019634
Publication Date: 30.11.2017 International Filing Date: 26.05.2017
IPC:
C07D 253/06 (2006.01), A61K 31/53 (2006.01), A61P 3/10 (2006.01), A61P 9/00 (2006.01), A61P 11/00 (2006.01), A61P 15/00 (2006.01), A61P 19/02 (2006.01), A61P 19/10 (2006.01), A61P 25/00 (2006.01), A61P 25/06 (2006.01), A61P 29/00 (2006.01), A61P 31/04 (2006.01), A61P 35/00 (2006.01), A61P 43/00 (2006.01), C07D 401/12 (2006.01), C07D 405/12 (2006.01), C07D 405/14 (2006.01), C07D 413/04 (2006.01), C07D 413/14 (2006.01)
Applicants: SHIONOGI & CO., LTD. [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP)
Inventors: KAI, Hiroyuki; (JP)
Agent: YAMAUCHI, Hideaki; (JP).
SUGITA, Ken-ichi; (JP)
Priority Data:
2016-105718 27.05.2016 JP
Title (EN) 5-OXO-1,2,4-TRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF
(FR) DÉRIVÉ DE 5-OXO-1,2,4-TRIAZINE ET COMPOSITION PHARMACEUTIQUE CORRESPONDANTE
(JA) 5-オキソ-1,2,4-トリアジン誘導体およびその医薬組成物
Abstract: front page image
(EN)The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound represented by formula (I): (wherein, R1 represents a substituted or unsubstituted alkyl or the like, R2 represents a substituted or unsubstituted aromatic carbon cyclic group or the like, R3 represents a substituted or unsubstituted aromatic carbon cyclic group or the like, each R4a independently represents a hydrogen atom or the like, each R4b independently represents a hydrogen atom or the like, n represents an integer of 0-4, X represents -N(R5)- or the like, R5 represents a hydrogen atom or the like), or a pharmaceutically acceptable salt thereof.
(FR)La présente invention concerne un nouveau composé antagoniste du récepteur P2X3 et/ou P2X2/3. L'invention porte sur un composé représenté par la formule (I) : (dans laquelle R1 représente alkyle substitué ou non substitué ou analogue, R2 représente un groupe carboné cyclique aromatique substitué ou non substitué ou analogue, R3 représente un groupe carboné cyclique aromatique substitué ou non substitué ou analogue, chaque R4a représente, indépendamment, un atome d'hydrogène ou analogue, chaque R4b représente, indépendamment, un atome d'hydrogène ou analogue, n représente un entier de 0-4, X représente -N(R5)- ou analogue, R5 représente un atome d'hydrogène ou analogue) ou sur un sel pharmaceutiquement acceptable correspondant.
(JA)本発明は、新規なP2X3および/またはP2X2/3受容体拮抗作用を有する化合物を提供する。 式(I):(式中、Rは置換若しくは非置換のアルキル等、Rは置換若しくは非置換の芳香族炭素環式基等、Rは置換若しくは非置換の芳香族炭素環式基等、R4aはそれぞれ独立して水素原子等、R4bはそれぞれ独立して水素原子等、nは0~4の整数、Xは-N(R)-等、Rは水素原子等)で示される化合物またはその製薬上許容される塩。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)